TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02476916

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AG-348
Description: Participants with PK deficiency were randomized to either receive AG-348, 50 or 300 mg, as initial doses, BID for the Core Period (Week 24). At the Week 24 visit, Core Period participants who had safely tolerated AG-348 and demonstrated clinical activity in response to AG-348 were potentially eligible to immediately roll over to the Extension Period for continued treatment. Participants were assigned to initial doses, however, over the course of the core period were treated across a range of doses due to treatment emergent adverse events (AEs) and hemoglobin (Hb) levels exceeding mid-point of sex-adjusted ranges.
Study: NCT02800005

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AFA group (successive patients)
Description: The abdominal fat area at the umbilical level was measured using a CT scanner(sango Mount Monitor Wireless Panel; Siemens , Munich, Germany) while the examinee was in a supine position and estimated using a Volume software (fat Pointer; Siemens , Munich, Germany). The imaging conditions were 120 kilovolt and 50 milliampere, using a 5-mm-thick slice.The areas covered by visceral fat software calculated from pixels with densities ranging from-190 to -30 hounsfield unit . No contrast agent is needed.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BMI group (successive patients)
Description: The formula for BMI is weight in kilograms divided by height in meters squared (kg/m2). the normal range is usually considered to be 18.5 to 24.9, with less than 18.5 considered underweight, more than 25.0 considered overweight and above 30.0 obese.

Intervention type: OTHER
Group type: OTHER
Intervention: BMI group (successive patients)
Description: The formula for BMI is weight in kilograms divided by height in meters squared (kg/m2). the normal range is usually considered to be 18.5 to 24.9, with less than 18.5 considered underweight, more than 25.0 considered overweight and above 30.0 obese.
Study: NCT01084148

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: V0034CR01B

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: V0034CR01B vehicle
Study: NCT02757352

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixekizumab
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixekizumab
Description: Administered SC

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC
Study: NCT03092570

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: With stimulation
Description: ramp stimulation from 0 to 2 mA followed by 20 minutes of stimulation at 2mA while practicing during 3 of the 4 sessions

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: With stimulation
Description: ramp stimulation from 0 to 2 mA followed by 20 minutes of stimulation at 2mA while practicing during 3 of the 4 sessions

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: With stimulation
Description: ramp stimulation from 0 to 2 mA followed by 20 minutes of stimulation at 2mA while practicing during 3 of the 4 sessions

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: No stimulation
Description: ramp stimulation from 0 to 2 mA followed by 30 sec of stimulation at 2mA.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: No stimulation
Description: ramp stimulation from 0 to 2 mA followed by 30 sec of stimulation at 2mA.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: No stimulation
Description: ramp stimulation from 0 to 2 mA followed by 30 sec of stimulation at 2mA.
Study: NCT02843815

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cryosurgery
Description: Argon-helium cryosurgical system (percutaneous ablation under CT or ultrasound guidance)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cryosurgery
Description: Argon-helium cryosurgical system (percutaneous ablation under CT or ultrasound guidance)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NK Immunotherapy
Description: Natural killer cell (each treatment: about 10 billion cells transfusion in 3 times, i.v.)
Study: NCT05492747

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kangaroo Care an Effect
Description: Researchers evaluated vital signs and oxygen saturation of preterm infants in the kangaroo care group 15 minutes before kangaroo care. After the baby's mother was admitted to the NICU, she was assisted by the researcher for hand hygiene and they went to the incubator together. The mother was seated in a comfortable chair next to the incubator. After the researcher covered the head and back of the preterm baby with a baby blanket, she took it from the incubator and placed it between the mother's breasts, with the head up and upright. The baby was supported not only by the neck and shoulders, but also by the whole body. Skin contact between mother and baby was ensured at the highest level. The baby was positioned so that its lips were touching the mother's nipple. The researcher waited until the baby opened its mouth.
Study: NCT03565003

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JAB-3068
Description: 25 mg,100 mg
Study: NCT01237288

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Z-521
Study: NCT01225926

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Toric T3 - T9
Description: Commercially available, acrylic, multifocal IOL intended to provide visual correction over the lifetime of the cataract patient

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: IQ SN60WF
Description: Commercially available, acrylic, monofocal IOL intended to provide visual correction over the lifetime of the cataract patient
Study: NCT04481594

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HPN-01
Description: 25 mg, 50 mg, 100 mg, 150 mg, 200 mg and 300 mg HPN-01 capsules

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 25 mg, 50 mg, 100 mg, 150 mg, 200 mg and 300 mg HPN-01 placebo capsules
Study: NCT01013831

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib Hydrochloride
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study: NCT03864991

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: e-device for step count (fit-bit)
Description: Patients in this group will receive fitbit device to count their daily steps and record it into their log books.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: e-device for step count (fit-bit)
Description: Patients in this group will receive fitbit device to count their daily steps and record it into their log books.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: e-messages for log book
Description: Patients in this group will receive e-messages to maintain their log books as per instruction for blood sugar levels and send back weekly through snap shot.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: e-messages for log book & fit-bit
Description: Patient in this group will receive e-messages to maintain their log books for blood sugar levels as well as use fitbit device and maintain their log book for daily step count and send back weekly through snap shot.
Study: NCT03197467

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab at fixed dose: 200 mg q3w i.v. for 2 cycles
Study: NCT02494895

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor monotherapy
Description: Ticagrelor (Brilinta®) is indicated for the prevention of thrombotic events (for example stroke or heart attack) in people with acute coronary syndrome or myocardial infarction with ST elevation. Patients will be randomized to stop aspirin at 3 months after PCI.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ticagrelor with Aspirin DAPT(dual antiplatelet treatment)
Description: Ticagrelor (Brilinta®) is indicated for the prevention of thrombotic events (for example stroke or heart attack) in people with acute coronary syndrome or myocardial infarction with ST elevation. Patients will be randomized to continue DAPT (aspirin+ticagrelor) up to 1 year.
Study: NCT00716768

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic Inguinal Hernia Repair
Description: Laparoscopic Inguinal Hernia Repair

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open Inguinal Hernia Repair
Description: Open Inguinal Hernia Repair
Study: NCT02155309

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Scopolamine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03003169

Intervention type: OTHER
Intervention: Medical questionnaire
Description: * quality of life questionnaire (EORTC QLQ-C30 and QLQ-BR23)~* Hospital Anxiety and Depression scale~* satisfaction care questionnaire (IN-PATSAT32)
Study: NCT03241576

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Small portion size provision
Description: The intervention is the small meal size participants are provided with during a lunchtime session in the laboratory.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Large portion size provision
Description: The intervention is the large meal size participants are provided with during a lunchtime session in the laboratory.
Study: NCT00826098

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Platelet Rich Plasma
Description: Addition of PRP to total knee replacement procedure
Study: NCT00844779

Intervention type: PROCEDURE
Intervention: Bariatric surgery
Description: Gastric bypass.

Intervention type: PROCEDURE
Intervention: Bariatric surgery
Description: Gastric bypass.

Intervention type: PROCEDURE
Intervention: cholecystectomy or benign liver tumor removal
Description: cholecystectomy or benign liver tumor removal
Study: NCT01427010

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: [18F]FDG-PET-voxel intensity-based IMRT
Description: Non-controlled, non-randomized, prospective study on 18F-Fluorodeoxyglucose-Positron Emission Tomography (\[18F\]FDG-PET)-voxel intensity-based intensity-modulated radiotherapy (IMRT) (dose painting) adapted to the anatomical and biological changes as detected by per-treatment FDG-PET/Computertomography (CT) acquired at the end of the 2nd and the 4th week of treatment.
Study: NCT03111277

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Experimental: ExAblate Transcranial treatment
Description: Patients' head will be placed in a device to hold it still for the treatment. Patients will lie headfirst on the ExAblate table. The ExAblate Transcranial helmet will be placed on their head. A device will be placed over their head to hold it and the helmet still. The investigators will measure the study participant's heart, blood pressure, temperature, and breathing rate before the treatment begins. MRI scans will be taken to make sure the ultrasound waves will be aimed exactly within the target. The space between the rubber diaphragm and the helmet will be filled with water. The water will be chilled to avoid heating of the scalp and skull during the ultrasound treatment. A series of MR images will be taken to identify the target area, and plan the study treatment. The study investigators will decide on the area of participant's brain that will be treated. The ExAblate Transcranial system will compute a plan to cover the treatment area.
Study: NCT04304508

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY2433334
Description: Tablet, taken orally once a day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY2433334
Description: Tablet, taken orally once a day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY2433334
Description: Tablet, taken orally once a day.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: BAY2433334 matching placebo
Description: Tablet, taken orally once a day.
Study: NCT00703677

Intervention type: DRUG
Group type: OTHER
Intervention: Lithium
Description: All participants will receive lithium. The dosage will be titrated over a 5-week period and then continued for an additional 6 months.
Study: NCT01450514

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pipamperone
Description: 15 mg PIP once daily per os on top of continued stable treatment with RIS or PAL

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: matching placebo sugar pill once daily per os on top of continued stable treatment with RIS or PAL
Study: NCT02809352

Intervention type: BIOLOGICAL
Intervention: Human papillomavirus genotyping
Study: NCT00208260

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FOLFIRI
Description: FOLFIRI : Irinotecan : 180 mg/m² 90 min continuous perfusion during levorin d1 every 2 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FOLFOX-4
Description: FOLFOX 4 : Oxaliplatine : 85 mg/m² 2h continuous perfusion during levorin d1 every 2weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRI-HD
Description: High Dose FOLFIRI : Irinotecan : 260 mg/m² in 90min continuous perfusion during levorin d1 every 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOX-7
Description: FOLFOX 7 : Oxaliplatine : 130 mg/m² in 2h continuous perfusion during levorin d1 every 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRINOX
Description: FOLFIRINOX : Oxaliplatine : 85 mg/m² 2h continuous perfusion followed by 1H rest followed by 90 min continuous perfusion of irinotecan : 180 mg/m² during levorin d1 every 2 weeks
Study: NCT01523834

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panobinostat
Description: Induction Phase: Patients will receive panobinostat for 6 courses (1 course = 28 days). Consolidation phase (courses 7-12). Maintenance phase (course 13-end of therapy).~Panobinostat should be taken p.o. at the dose of 40 mg/day 3-times every week (QW) as part of a 4 week treatment cycle. The dose of panobinostat may be modified: the 1st dose adjustment consists in the modification of drug administration from 3 times every week (QW) to 3 times every other week (QOW). Levels lower than 30 mg 3 times QOW is not permitted.
Study: NCT01535469

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluconazole
Description: Fluconazole 800mg orally daily for 2 weeks, then 400mg daily for 8 weeks
Study: NCT01963559

Intervention type: DRUG
Group type: OTHER
Intervention: Lidocaine/prilocaine 1g (topical administration)
Description: Cutaneous blood flow measurement using laser Doppler
Study: NCT04116437

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanubrutinib
Description: Zanubrutinib (BGB-3111) will be orally administered at a dose of 160 mg twice daily or 320mg once daily until disease progression, unacceptable toxicity, treatment consent withdrawal, or study termination.
Study: NCT03555448

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Once daily immunosuppression regimen
Description: Intervention focuses on the type of regimen, in this case the intervention arm will receive a once daily regimen for immunosuppression compared to the twice daily regimen.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Twice daily immunosuppression regimen
Description: This is the arm which we are designating the standard, which will be the comparison to the active drug arm.
Study: NCT04342572

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: -The drug is commerically available
Study: NCT02138617

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil
Description: 400 mg/m2 IV bolus followed by 2400 mg/m2 IV over 46 hours, Day 1 and Day 15 .

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil
Description: 400 mg/m2 IV bolus followed by 2400 mg/m2 IV over 46 hours, Day 1 and Day 15 .

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil
Description: 400 mg/m2 IV bolus followed by 2400 mg/m2 IV over 46 hours, Day 1 and Day 15 .

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: 200-400 mg/m2 IV over 2 hours, Day 1 and Day 15

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: 200-400 mg/m2 IV over 2 hours, Day 1 and Day 15

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: 200-400 mg/m2 IV over 2 hours, Day 1 and Day 15

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: IV infusion over 90 minutes, dosed at 180, 260 or 310 mg/m2 based on genotype.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: IV infusion over 90 minutes, dosed at 180, 260 or 310 mg/m2 based on genotype.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: IV infusion over 90 minutes, dosed at 180, 260 or 310 mg/m2 based on genotype.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab (5 mg/kg IV infused as per institutional policy, IV, Day 1, 15)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab (5 mg/kg IV infused as per institutional policy, IV, Day 1, 15)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab (5 mg/kg IV infused as per institutional policy, IV, Day 1, 15)
Study: NCT04613596

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adagrasib
Description: Adagrasib 400 mg twice daily (BID) in combination with pembrolizumab (Cohort 1a)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adagrasib
Description: Adagrasib 600 mg BID monotherapy (Cohort 1b)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adagrasib
Description: adagrasib 400 mg BID in combination with pembrolizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adagrasib
Description: Adagrasib 400 mg BID + pembrolizumab 200 mg every Q3W

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: Pembrolizumab 200 mg IV Q3W
Study: NCT02502435

Intervention type: OTHER
Intervention: Observation
Description: Observational study

Intervention type: OTHER
Intervention: Observation
Description: Observational study
Study: NCT01166711

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Coroflex Blue (BMS) followed by SeQuent Please (DEB)
Description: * standard techniques will be used~* maximal vasodilatation after nitro application~* baseline angiography with at least two orthogonal views (showing target lesion free of foreshortening or vessel overlap)~* 6 French guiding catheter at least~* target lesion will be crossed with standard guidewire~* direct stenting at the discretion of the investigator~* if pre-dilation, a commercially available balloon will be used (length not exceeding the stent to be implanted)~* full lesion coverage will be ensured (with one or more stents)~* only insert assigned stent type~* BMS needs to be fully embedded in vessel wall~* post-dilation with high pressure is required before treatment with DEB~* DEB will be inflated with nominal pressure (balloon equates to vessel diameter)~* length of DEB should exceed the BMS by 2-3 mm on each side~* if dissection, full length of dissection and optional additional stented area should be treated with additional DEB (to avoid geographic miss)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Coroflex Please (DES)
Description: * standard techniques will be used~* maximal vasodilatation after nitro application~* baseline angiography with at least two orthogonal views (showing target lesion free of foreshortening or vessel overlap)~* 6 French guiding catheter at least~* target lesion will be crossed with standard guidewire~* direct stenting at the discretion of the investigator~* if pre-dilation, a commercially available balloon will be used (length not exceeding the stent to be implanted)~* full lesion coverage will be ensured (with one or more stents)~* only insert assigned stent type
Study: NCT01913574

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Acupuncture is applied three times a week for 20 minutes for 2 weeks (total 6 sessions). 9 Acupuncture points, CV12, CV13, P6, SP4, ST36(bilateral),LI4 (bilateral), LR3 (bilateral), ST34 (bilateral), and GB21(bilateral) are used, and CV12, CV13, ST36, and LR3 are electro-stimulated.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Neurolytic celiac plexus block (NCPB)
Description: An anaesthetic test is performed injecting 2ml mepivacaine. After assessing the efficacy and safety of this test, 10 ml of absolute alcohol is injected via each needle.
Study: NCT03838159

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Paclitaxel must be administered by infusion over 3 hours in dextrose (D5W) or normal saline (NS). The concentration must not exceed 1.2 mg/ml.~The infusions must be mixed as soon as possible before the start of each infusion since the stability of paclitaxel beyond 24 hours is not known.~In-line filtration is obligatory since a small number of fibers within the acceptable limits of the USP Particulate Matter Test for LVP have been reported. Cellulose acetate filters of 0.22-micron pore size (such as IVEX II) can be used. The solution that shows excessive particulate matter must be rejected.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel must be administered by infusion over 3 hours in dextrose (D5W) or normal saline (NS). The concentration must not exceed 1.2 mg/ml.~The infusions must be mixed as soon as possible before the start of each infusion since the stability of paclitaxel beyond 24 hours is not known.~In-line filtration is obligatory since a small number of fibers within the acceptable limits of the USP Particulate Matter Test for LVP have been reported. Cellulose acetate filters of 0.22-micron pore size (such as IVEX II) can be used. The solution that shows excessive particulate matter must be rejected.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Carboplatin must be administered at the end of the Paclitaxel infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin must be administered at the end of the Paclitaxel infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab is a soluble protein consisting of 4 polypeptide chains, which include 2 identical heavy chains and 2 identical light chains.~The administration of nivolumab infusion must be completed within 24 hours of preparation.